We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Find out more Skip to Main Content

Annals of Oncology Award (JSMO 2016)

Annals of Oncology is a multidisciplinary journal on medical oncology, surgery, radiotherapy, paediatric oncology, basic research and management of patients with malignant diseases, and is the official journal of the European Society for Medical Oncology (ESMO) and the Japanese Society of Medical Society (JSMO). 

Each year, JSMO selects the most successful articles from Japanese authors, and chooses one to win the Annals of Oncology Award (JSMO 2016) . Read this year's winning paper by Dr Koichi Azuma:

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

To mark JSMO 2016 (28-30 July) we have put together a free online collection of the nominated papers for this year's prize.

Nominated Articles

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
H. Saito et al.

The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors
N. Yamamoto et al.

Solid tumor size on high-resolution computed tomography and maximum standardized uptake on positron emission tomography for new clinical T descriptors with T1 lung adenocarcinoma
Y. Tsutani et al.

Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours
A. Miyanaga et al.

Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912
Y. Yamada et al.

Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II–IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016)
K. Harano et al.

Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification
R. Noro et al.

Irsogladine maleate reduces the incidence of fluorouracil-based chemotherapy-induced oral mucositis
M. Nomura et al.

S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
M. Yoshida et al.

Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209
H. Kitamura et al.

Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
S. Nishiwaki et al.

Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study
H. Yoshioka et al.

Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer
A. Tamiya et al.

JSMO 2016

Read the JSMO 2016 conference abstracts now

More from Annals

Instructions to authors - English

Instructions to authors - Japanese

Follow us on Twitter for all the latest news

Never miss an issue by signing up to eTOC alerts

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Subscribe Now